Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad)
LON:SCLP

Scancell 1/30/2025 Earnings Report

Scancell logo
GBX 9.90 -0.10 (-1.00%)
As of 05:46 AM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 1.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Date
1/30/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Scancell (LON:SCLP) Stock Price Up 7% Following Insider Buying Activity
May 23 at 2:27 AM | americanbankingnews.com
Scancell (LON:SCLP) Shares Up 7% Following Insider Buying Activity
May 23 at 1:04 AM | americanbankingnews.com
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
May 23, 2025 | Timothy Sykes (Ad)
Scancell (LON:SCLP) Trading 7% Higher After Insider Buying Activity
May 23 at 1:03 AM | americanbankingnews.com
Scancell (LON:SCLP) Shares Up 7% on Insider Buying Activity
May 22 at 3:16 AM | americanbankingnews.com
Scancell Hldgs Plc (SCLP)
February 22, 2025 | uk.investing.com
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

View Scancell Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles